Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY 4.0Medical Principles and Practice

Clinical Significance of Klotho, Fibroblast Growth Factor 23, and Their Ratio for Acute Kidney Injury in Sepsis Patients

  • Sumian Dou1
  • Yuchao Shen1
  • Botao Zhao2
  • Ling Wang1
  • Wei Zhang1
  • Jing Wang3
  • Chunxue Wu1
  • Long Yang1
  • Zhanghai Sun4
  • Ying Cui1
4 affiliations
  1. 1West Branch Emergency Department, Cangzhou Central Hospital, Cangzhou, Hebei, China
  2. 2Cangzhou Central Hospital, The Fifth Department of Coronary Heart Disease, Cangzhou, Hebei, China
  3. 3Department of Oral Pathology, Cangzhou Medical College, Cangzhou, Hebei, China
  4. 4Department of Mental Health Education, Cangzhou Medical College, Cangzhou, Hebei, China
Read full textPDFDOICite

Abstract

Objective: The sepsis-associated acute kidney injury (SA-AKI) is common in patients with sepsis and associated with poor outcomes, yet serum creatinine and urine output have limited value for early assessment. We examined whether admission Klotho, fibroblast growth factor 23 (FGF23), and the Klotho/FGF23 ratio were associated with SA-AKI and short-term outcomes and compared their discriminative performance.

Methods: We conducted a retrospective cohort study of 320 patients admitted to the intensive care unit (ICU) with Sepsis-3-defined sepsis. SA-AKI (n = 112) was retrospectively identified according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Klotho and FGF23 were measured by enzyme-linked immunosorbent assay in stored serum samples collected within 24 h of ICU admission. Discrimination was assessed by receiver operating characteristic analysis, and adjusted associations were evaluated using multivariable logistic and linear regression.

Results: Patients with SA-AKI had lower Klotho, higher FGF23, and a reduced Klotho/FGF23 ratio at admission (all p < 0.001). The ratio showed the highest area under the curve biomarkers for SA-AKI (0.84; 95% confidence interval 0.79–0.88) and remained associated with SA-AKI after multivariable adjustment (odds ratio 2.25; 95% confidence interval 1.46–3.53). The ratio decreased with increasing KDIGO stage. Among patients with SA-AKI, a low ratio remained associated with lower 3-month renal recovery, longer ICU and hospital stays, higher in-hospital mortality, and greater 3-month chronic kidney disease progression after adjustment.

Conclusion: The admission Klotho/FGF23 ratio was associated with SA-AKI, higher KDIGO stage, and short-term outcomes and showed the highest observed discrimination among the three biomarkers.

Related

  1. Changes of serum fibroblast growth factor 23 (FGF23) and Klotho in diabetic kidney disease and their correlation with coronary artery calcification: a retrospective study.
    Yan Hong, Jiahui Wang, Qiandi Lu +2
    Archives of endocrinology and metabolismPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  2. Fibroblast Growth Factor 23 and Osteoprotegerin in Vascular Calcification among Patients without Advanced Chronic Kidney Disease
    Keisuke Senda, Nami Teraoka, Kazuma Masuda +6
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis
    Sehreen Tory, Md. Mojahidur Hasan, Yusuf Kemal Arslan +2
    Asian Pacific Journal of Cancer Prevention : APJCPPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  4. Prognostic Significance and Clinical Robustness of the HALP Score in Super-Elderly Patients Undergoing Curative Gastrectomy for Gastric Cancer: A Multicenter Retrospective Cohort Study.
    Hiroyuki Inoue, Takeshi Kubota, Toshiyuki Kosuga +14
    Annals of gastroenterological surgeryPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban.
    Parwana Hussaini, Trine-Lise Larsen, Waleed Ghanima +1
    Research and practice in thrombosis and haemostasisPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{dou2026clinical,
  title = {{Clinical Significance of Klotho, Fibroblast Growth Factor 23, and Their Ratio for Acute Kidney Injury in Sepsis Patients}},
  author = {Sumian Dou and Yuchao Shen and Botao Zhao and Ling Wang and Wei Zhang and Jing Wang and Chunxue Wu and Long Yang and Zhanghai Sun and Ying Cui},
  journal = {Medical Principles and Practice},
  year = {2026},
  month = oct,
  doi = {10.1159/mpp/adpag028},
  url = {https://doi.org/10.1159/mpp/adpag028},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Clinical Significance of Klotho, Fibroblast Growth Factor 23, and Their Ratio for Acute Kidney Injury in Sepsis Patients
AU  - Sumian Dou
AU  - Yuchao Shen
AU  - Botao Zhao
AU  - Ling Wang
AU  - Wei Zhang
AU  - Jing Wang
AU  - Chunxue Wu
AU  - Long Yang
AU  - Zhanghai Sun
AU  - Ying Cui
PY  - 2026
DA  - 2026/10/09
JO  - Medical Principles and Practice
DO  - 10.1159/mpp/adpag028
UR  - https://doi.org/10.1159/mpp/adpag028
AB  - Objective: The sepsis-associated acute kidney injury (SA-AKI) is common in patients with sepsis and associated with poor outcomes, yet serum creatinine and urine output have limited value for early assessment. We examined whether admission Klotho, fibroblast growth factor 23 (FGF23), and the Klotho/FGF23 ratio were associated with SA-AKI and short-term outcomes and compared their discriminative performance.  Methods: We conducted a retrospective cohort study of 320 patients admitted to the intensive care unit (ICU) with Sepsis-3-defined sepsis. SA-AKI (n = 112) was retrospectively identified according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Klotho and FGF23 were measured by enzyme-linked immunosorbent assay in stored serum samples collected within 24 h of ICU admission. Discrimination was assessed by receiver operating characteristic analysis, and adjusted associations were evaluated using multivariable logistic and linear regression.  Results: Patients with SA-AKI had lower Klotho, higher FGF23, and a reduced Klotho/FGF23 ratio at admission (all p < 0.001). The ratio showed the highest area under the curve biomarkers for SA-AKI (0.84; 95% confidence interval 0.79–0.88) and remained associated with SA-AKI after multivariable adjustment (odds ratio 2.25; 95% confidence interval 1.46–3.53). The ratio decreased with increasing KDIGO stage. Among patients with SA-AKI, a low ratio remained associated with lower 3-month renal recovery, longer ICU and hospital stays, higher in-hospital mortality, and greater 3-month chronic kidney disease progression after adjustment.  Conclusion: The admission Klotho/FGF23 ratio was associated with SA-AKI, higher KDIGO stage, and short-term outcomes and showed the highest observed discrimination among the three biomarkers.
SN  - 1011-7571
SN  - 1423-0151
ER  -